Combination of an insulin and a GLP-1 agonist
The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.
1. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of:
(a) insulin glargine or a pharmaceutically acceptable salt thereof, and
(b) desPro 36 exendin-4(1-39)-Lys 6 -NH 2 (AVE0010) or a pharmaceutically acceptable salt thereof;
wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 33 μg/mL; and
wherein the prefilled syringe is configured to administer the pharmaceutical formulation at a dosage of insulin glargine between about 15 units and about 80 units and a dosage of AVE0010 between about 5 μg and about 2 mg.
2. The prefilled syringe of claim 1 ,
wherein the prefilled syringe is configured to administer the pharmaceutical formulation at a dosage of insulin glargine between about 15 units and about 60 units and a dosage of AVE0010 between about 5 μg and about 20 μg.
3. The prefilled syringe of claim 1 ,
wherein the prefilled syringe is configured to administer the pharmaceutical formulation at a dosage of insulin glargine between about 15 units and about 80 units and a dosage of AVE0010 between about 5 μg and about 20 μg.
4. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of:
(a) insulin glargine or a pharmaceutically acceptable salt thereof, and
(b) desPro 36 exendin-4(1-39)-Lys 6 -NH 2 (AVE0010) or a pharmaceutically acceptable salt thereof;
wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 20 m/ml to about 150 μg/ml.
5. The prefilled syringe of claim 4 ,
wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 25, 33, 40, 66, or 75m/mL.
6. The prefilled syringe of claim 4 ,
wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 33 μg/mL.
7. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of:
(a) insulin glargine or a pharmaceutically acceptable salt thereof, and
(b) desPro 36 exendin-4(1-39)-Lys 6 -NH 2 (AVE0010) or a pharmaceutically acceptable salt thereof;
wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL, and
wherein the ratio of insulin glargine and AVE0010 in the pharmaceutical formulation is about 1.5 units to about 4 units of insulin glargine to 1 μg of AVE0010.
8. The prefilled syringe of claim 7 ,
wherein the ratio of insulin glargine and AVE0010 in the pharmaceutical formulation is about 3 units of insulin glargine to 1 μg of AVE0010.